Arcutis Biotherapeutics Inc [ARQT] stock is trading at $10.77, up 6.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARQT shares have gain 14.21% over the last week, with a monthly amount glided 23.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on August 28, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $15. Previously, Mizuho upgraded its rating to Buy on January 03, 2024, and elevated its price target to $8. On October 26, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $6 on October 13, 2023. Needham initiated its recommendation with a Buy and recommended $46 as its price target on September 07, 2022. Goldman started tracking with a Buy rating for this stock on March 17, 2022, and assigned it a price target of $45. In a note dated June 30, 2021, Mizuho initiated an Buy rating and provided a target price of $58 on this stock.
Arcutis Biotherapeutics Inc [ARQT] stock has fluctuated between $1.76 and $13.17 over the past year. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $10.77 at the most recent close of the market. An investor can expect a potential return of 187.84% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 138.71M for the trailing twelve months, which represents a growth of 17.44%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.41%, and Net Profit Margin reading is -1.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -1.19 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.29 points at the first support level, and at 9.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.18, and for the 2nd resistance point, it is at 11.58.
Ratios To Look Out For
For context, Arcutis Biotherapeutics Inc’s Current Ratio is 2.46. As well, the Quick Ratio is 2.38, while the Cash Ratio is 0.78. Considering the valuation of this stock, the price to sales ratio is 9.00, the price to book ratio is 8.04.
Transactions by insiders
Recent insider trading involved Burnett Patrick, Officer, that happened on Nov 22 ’24 when 16023.0 shares were purchased., Matsuda Masaru completed a deal on Nov 19 ’24 to sell 1775.0 shares. Meanwhile, Officer Matsuda Masaru bought 1775.0 shares on Nov 19 ’24.
